Leukemia Drugs Market Research Reports

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Acute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report

  • Report
  • 156 Pages
From
MarketVIEW: CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary - Product Thumbnail Image

MarketVIEW: CAR-T Cell Therapy For Multiple Myeloma Disease and Pipeline Summary

  • Report
  • 110 Pages
Myelodysplastic Syndrome (MDS) Drugs Market Size, Share & Trends Analysis By Therapeutic Class (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics), And Segment Forecasts, 2016 - 2022 - Product Thumbnail Image

Myelodysplastic Syndrome (MDS) Drugs Market Size, Share & Trends Analysis By Therapeutic Class (Hypomethylating Agents, Immunomodulatory Drugs, Anti-anemics), And Segment Forecasts, 2016 - 2022

  • Report
  • 67 Pages
From
Global Myelodysplastic Syndrome Therapeutics Market 2018-2022 - Product Thumbnail Image

Global Myelodysplastic Syndrome Therapeutics Market 2018-2022

  • Report
  • 119 Pages
From
Global Leukemia Partnering 2012 to 2018 - Product Thumbnail Image

Global Leukemia Partnering 2012 to 2018

  • Report
  • 150 Pages
From
Global Multiple Myeloma Partnering 2012 to 2018 - Product Thumbnail Image

Global Multiple Myeloma Partnering 2012 to 2018

  • Report
  • 150 Pages
From
Global Acute and Chronic Myelogenous Leukemia Partnering 2012 to 2018 - Product Thumbnail Image

Global Acute and Chronic Myelogenous Leukemia Partnering 2012 to 2018

  • Report
  • 150 Pages
From
Leukaemia Forecast in 18 Major Markets 2017-2027 - Product Thumbnail Image

Leukaemia Forecast in 18 Major Markets 2017-2027

  • Report
  • 82 Pages
From
BCMA Targeted Therapies, 2017-2030 - Product Thumbnail Image

BCMA Targeted Therapies, 2017-2030

  • Report
  • 143 Pages
From
Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments - Product Thumbnail Image

Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments

  • Report
  • 117 Pages
From
Primary Myelofibrosis Forecast in 8 Major Markets 2016-2026 - Product Thumbnail Image

Primary Myelofibrosis Forecast in 8 Major Markets 2016-2026

  • Report
  • 40 Pages
From
Acute Myeloid Leukemia - Heat Map and Analysis - Product Thumbnail Image

Acute Myeloid Leukemia - Heat Map and Analysis

  • Drug Pipelines
  • 10 Pages
From
CAS 97832-05-8 Bendamustine Chemical World Report - Product Thumbnail Image

CAS 97832-05-8 Bendamustine Chemical World Report

  • Report
  • 2025 Pages
CAS 943319-70-8 Ponatinib Chemical World Report - Product Thumbnail Image

CAS 943319-70-8 Ponatinib Chemical World Report

  • Report
  • 2051 Pages
CAS 97207-47-1 Meisoindigo Chemical World Report - Product Thumbnail Image

CAS 97207-47-1 Meisoindigo Chemical World Report

  • Report
  • 2029 Pages
CAS 57852-57-0 Idarubicin hydrochloride Chemical World Report - Product Thumbnail Image

CAS 57852-57-0 Idarubicin hydrochloride Chemical World Report

  • Report
  • 2031 Pages
CAS 58957-92-9 Idarubicin Chemical World Report - Product Thumbnail Image

CAS 58957-92-9 Idarubicin Chemical World Report

  • Report
  • 2185 Pages
CAS 67-78-7 Triamcinolone diacetate Chemical World Report - Product Thumbnail Image

CAS 67-78-7 Triamcinolone diacetate Chemical World Report

  • Report
  • 2116 Pages
CAS 69-74-9 Cytarabine hydrochloride Chemical World Report - Product Thumbnail Image

CAS 69-74-9 Cytarabine hydrochloride Chemical World Report

  • Report
  • 2171 Pages
CAS 76-25-5 Triamcinolone acetonide Chemical World Report - Product Thumbnail Image

CAS 76-25-5 Triamcinolone acetonide Chemical World Report

  • Report
  • 2159 Pages
Loading Indicator

On average over 40,000 are diagnosed with leukemia each year in the United States. It is also one of the most common cancers in children. Large differences in therapeutic outcomes exist among patient groups such as children and old age sufferers, and according to the form of a disease that has many variants such as Acute (AML) and Chronic (CML) Myelocytic Leukemia, Acute (ALL) and Chronic (CLL) Lymphocytic Leukemia, and Hairy Cell Leukemia (HCL). These variations have led to unmet needs among specific patient groups. The selection of expert and insightful reports in this section enable you explore these market opportunities by providing key industry data such as drug development strategies, international market trends and forecasts and profiles of major players like Novartis, Pfizer and Bristol-Myers Squibb. Show Less Read more

adroll